Neopterin, a prognostic marker in human malignancies

Cancer Letters

Volumn 287, Issue 1, 2010, Pages 13-22

  Sucher, Robert ^a   Schroecksnadel, Katharina ^a   Weiss, Guenter ^a   Margreiter, Raimund ^a   Fuchs, Dietmar ^a   Brandacher, Gerald ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

Cancer; Macrophages; Neopterin; Prognosis

Indexed keywords

CYTOKINE; GAMMA INTERFERON; NEOPTERIN; REACTIVE OXYGEN METABOLITE; TRYPTOPHAN;

ANEMIA; BIOCHEMISTRY; CACHEXIA; CANCER GROWTH; CANCER SURVIVAL; CARCINOGENESIS; CELL STIMULATION; CELLULAR IMMUNITY; DENDRITIC CELL; DEPRESSION; FATIGUE; HUMAN; IMMUNOLOGICAL TOLERANCE; LABORATORY DIAGNOSIS; MACROPHAGE; MALIGNANT NEOPLASTIC DISEASE; MEASUREMENT; MONOCYTE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN DEGRADATION; SHORT SURVEY; WEIGHT REDUCTION;

EID: 72049127518     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2009.05.008     Document Type: Review

References (132)

1. Boon T., and van der Bruggen P. Human tumor antigens recognized by T-lymphocytes. J. Exp. Med. 183 (1996) 725-729
2. Munn D.H., and Mellor A.L. Indoleamine 2,3-dioxygenase and tumor-induced tolerance. J. Clin. Invest. 117 (2007) 1147-1154
3. Brandacher G., Winkler C., Schroecksnadel K., Margreiter R., and Fuchs D. Antitumoral activity of interferon-gamma involved in impaired immune function in cancer patients. Curr. Drug Metab. 7 (2006) 599-612
4. Melichar B., Savary C., Kudelka A.P., Verschraegen C., Kavanagh J.J., Edwards C.L., Platsoucas C.D., and Freedman R.S. Lineage-negative human leukocyte antigen-DR+ cells with the phenotype of undifferentiated dendritic cells in patients with carcinoma of the abdomen and pelvis. Clin. Cancer Res. 4 (1998) 799-809
5. Ikeda H., Old L.J., and Schreiber R.D. The roles of IFN gamma in protection against tumor development and cancer immunoediting. Cytokine Growth Factor Rev. 13 (2002) 95-109
6. Dranoff G., and Mulligan R.C. Gene transfer as cancer therapy. Adv. Immunol. 58 (1995) 417-454
7. Murr C., Widner B., Wirleitner B., and Fuchs D. Neopterin as a marker for immune system activation. Curr. Drug Metabol. 3 (2002) 175-187
8. Reibnegger G., Fuchs D., Fuith L.C., Hausen A., Werner E.R., Werner-Felmayer G., and Wachter H. Neopterin as a marker for activated cell-mediated immunity: application in malignant disease. Cancer Detect. Prevent. 15 (1991) 483-490
9. Duch D.S., Bowers S.W., Woolf J.H., and Nichol C.A. Biopterin cofactor biosynthesis: GTP cyclohydrolase, neopterin and biopterin in tissues and body fluids of mammalian species. Life Sci. 35 (1984) 1895-1901
10. Huber C., Batchelor J.R., Fuchs D., Hausen A., Lang A., Niederwieser D., Reibnegger G., Swetly P., Troppmair J., and Wachter H. Immune response-associated production of neopterin. Release from macrophages primarily under control of interferon-gamma. J. Exp. Med. 160 (1984) 310-316
11. Wirleitner B., Reider D., Ebner S., Boeck G., Widner B., Jaeger M., Schennach H., Romani N., and Fuchs D. Monocyte-derived dendritic cells release neopterin. J. Leukocyte Biol. 72 (2002) 1148-1153
12. Hoffmann G., Wirleitner B., and Fuchs D. Potential role of immune system activation associated production of neopterin derivatives in humans. Inflammation Res. 52 (2003) 313-321
13. Prommegger R., Widner B., Murr C., Unger A., Fuchs D., and Salzer G.M. Neopterin: a prognostic variable in operations for lung cancer. Ann. Thorac. Surg. 70 (2000) 1861-1864
14. Weiss G., Kronberger P., Conrad F., Bodner E., Wachter H., and Reibnegger G. Neopterin and prognosis in patients with adenocarcinoma of the colon. Cancer Res. 53 (1993) 260-265
15. Marth C., Weger A., Muller-Holzner E., Zeimet A.G., Moncayo-Naveda H., Daxenbichler G., Reibnegger G., Fuchs D., Wachter H., and Dapunt O. The prognostic value of nuclear roundness and neopterin in ovarian cancer. Eur. J. Cancer 29A (1993) 1863-1868
16. Murr C., Bergant A., Widschwendter M., Heim K., Schrocksnadel H., and Fuchs D. Neopterin is an independent prognostic variable in females with breast cancer. Clin. Chem. 45 (1999) 1998-2004
17. Birk D., Gansauge F., Gansauge S., Schwarz A., and Beger H.G. Levels of serum neopterin are increased in pancreatic cancer patients and correlate with the prognosis. Eur. J. Med. Res. 4 (1999) 156-160
18. Volgger B., Aspisirengil C., Genser-Krimbacher E., Ciresa-Koenig A., Daxenbichler G., Fuchs D., Windbichler G., and Marth C. Prognostic significance of TPA versus SCC-Ag, CEA and neopterin in carcinoma of the uterine cervix. Cancer Lett. 262 (2008) 183-189
19. Sakurai A., and Goto M. Neopterin: isolation from human urine. J. Biochem. 61 (1967) 142-145
20. Wachter H., Hausen A., and Grassmayr K. Increased urinary excretion of neopterin in patients with malignant tumors and with virus diseases. Hoppe Seyler's Z. Physiol. Chem. 360 (1979) 1957-1960
21. Fuchs D., Hausen A., Huber C., Margreiter R., Reibnegger G., Spielberger M., and Wachter H. Pteridinausscheidung als Marker für alloantigen-induzierte Lymphozytenproliferation. Hoppe Seyler's Z. Physiol. Chem. 363 (1982) 661-664
22. Werner E.R., Werner-Felmayer G., Fuchs D., Hausen A., Reibnegger G., Yim J.J., Pfleiderer W., and Wachter H. Tetrahydrobiopterin biosynthetic activities in human macrophages fibroblasts, THP-1, and T 24 cells. GTP-cyclohydrolase I is stimulated by interferon-gamma, and 6-pyruvoyl tetrahydropterin synthase and sepiapterin reductase are constitutively present. J. Biol. Chem. 265 (1990) 3189-3192
23. Widner B., Mayr C., Wirleitner B., and Fuchs D. Oxidation of 7,8-dihydroneopterin by hypochlorous acid yields neopterin. Biochem. Biophys. Res. Commun. 275 (2000) 307-311
24. Gieseg S.P., Maghzal G., and Glubb D. Protection of erythrocytes by the macrophage synthesized antioxidant 7,8 dihydroneopterin. Free Radical Res. 34 (2001) 123-136
25. Andert S.E., Griesmacher A., Zuckermann A., and Müller M.M. Neopterin release from human endothelial cells is triggered by interferon-gamma. Clin. Exp. Immunol. 88 (1992) 555-558
26. Hofmann B., Bass H., Nishanian P., Faisal M., Figlin R.A., Sarna G.P., and Fahey J.L. Different lymphoid cell populations produce varied levels of neopterin, beta 2-microglobulin and soluble IL-2, receptor when stimulated with IL-2 interferon-gamma or tumour necrosis factor-alpha. Clin. Exp. Immunol. 88 (1992) 548-554
27. Fuchs D., Murr C., Reibnegger G., Weiss G., Werner E.R., Werner-Felmayer G., and Wachter H. Nitric oxide synthase and antimicrobial armature of human macrophages. J. Infect. Dis. 169 (1994) 224
28. Weiss G., Schwaighofer H., Herold M., Nachbaur D., Wachter H., Niederwieser D., and Werner E.R. Nitric oxide formation as predictive parameter for acute graft-versus-host disease after human allogeneic bone marrow transplantation. Transplantation 60 (1995) 1239-1244
29. Chang T.W., McKinney S., Liu V., Kung P.C., Vilcek J., and Le J. Use of monoclonal antibodies as sensitive and specific probes for biologically active human gamma-interferon. Proc. Natl. Acad. Sci. USA 81 (1984) 5219-5222
30. Perussia B. Lymphokine-activated killer cells, natural killer cells and cytokines. Curr. Opin. Immunol. 3 (1991) 49-55
31. Sad S., Marcotte R., and Mosmann T.R. Cytokine-induced differentiation of precursor mouse CD8+ T cells into cytotoxic CD8+ T cells secreting Th1 or Th2 cytokines. Immunity 2 (1995) 271-279
32. Fuchs D., Weiss G., Reibnegger G., and Wachter H. The role of neopterin as a monitor of cellular immune activation in transplantation, inflammatory, infectious, and malignant diseases. Crit. Rev. Clin. Lab. Sci. 29 (1992) 307-341
33. Diez-Ruiz A., Tilz G.P., Zangerle R.G., Baier-Bitterlich, Wachter H., and Fuchs D. Soluble receptors for tumor necrosis factor in clinical laboratory diagnosis. Eur. J. Haematol. 54 (1995) 1-8
34. Fuchs D., Moeller A.A., Reibnegger G., Werner E.R., Werner-Felmayer G., Dierich M.P., and Wachter H. Increased endogenous interferon-gamma and neopterin correlate with increased degradation of tryptophan in human immunodeficiency virus type 1 infection. Immunol. Lett. 28 (1991) 207-211
35. Fuchs D., Norkrans G., Wejstal R., Reibnegger G., Weiss G., Weiland O., Schvarcz R., Fryden A., and Wachter H. Changes of serum neopterin, beta 2-microglobulin and interferon-gamma in patients with chronic hepatitis C treated with interferon-alpha 2b. Eur. J. Med. 1 (1992) 196-200
36. Denz H., Fuchs D., Huber H., Nachbaur D., Reibnegger G., Thaler J., Werner E.R., and Wachter H. Correlation between neopterin, interferon-gamma and haemoglobin in patients with haematological disorders. Eur. J. Haematol. 44 (1990) 186-189
37. Weiss G., Murr C., Zoller H., Haun M., Widner B., Ludescher C., and Fuchs D. Modulation of neopterin formation and tryptophan degradation by Th1- and Th2-derived cytokines in human monocytic cells. Clin. Exp. Immunol. 116 (1999) 435-440
38. Werner-Felmayer G., Werner E.R., Fuchs D., Hausen A., Reibnegger G., and Wachter H. Tumour necrosis factor-alpha and lipopolysaccharide enhance interferon-induced tryptophan degradation and pteridine synthesis in human cells. Biol. Chem. Hoppe Seyler 370 (1989) 1063-1069
39. Fuchs D., Stahl-Hennig C., Gruber A., Murr C., Hunsmann G., and Wachter H. Neopterin--its clinical use in urinalysis. Kidney Int. 47 (1994) S8-S11
40. Laich A., Neurauter G., Wirleitner B., and Fuchs D. Degradation of serum neopterin during daylight exposure. Clin. Chim. Acta. 322 (2002) 175-178
41. Mayersbach P., Augustin R., Schennach H., Schoenitzer D., Werner E.R., Wachter H., and Reibnegger G. Commercial enzyme-linked immunosorbent assay for neopterin detection in blood donations compared with RIA and HPLC. Clin. Chem. 40 (1994) 265-266
42. Schroecksnadel K., Winkler C., and Fuchs D. Method for urinary neopterin measurements by HPLC. J. Biochem. Biophys. Methods 66 (2006) 99-100
43. Werner E.R., Bichler A., Daxenbichler G., Fuchs D., Fuith L.C., Hausen A., Hetzel H., Reibnegger G., and Wachter H. Determination of neopterin in serum and urine. Clin. Chem. 33 (1987) 62-66
44. Flavall E.A., Crone E.M., Moore G.A., and Gieseg S.P. Dissociation of neopterin and 78-dihydroneopterin from plasma components before HPLC analysis. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 863 (2008) 167-171
45. Nathan C.F. Peroxide and pteridine: a hypothesis on the regulation of macrophage antimicrobial activity by interferon gamma. Interferon 7 (1986) 125-143
46. Murr C., Fuith L.C., Widner B., Wirleitner B., Baier-Bitterlich G., and Fuchs D. Increased neopterin concentrations in patients with cancer: indicator of oxidative stress?. Anticancer Res. 19 (1999) 1721-1728
47. Weiss G., Fuchs D., Hausen A., Reibnegger G., Werner E.R., Werner-Felmayer G., Semenitz E., Dierich M.P., and Wachter H. Neopterin modulates toxicity mediated by reactive oxygen and chloride species. FEBS Lett. 321 (1993) 89-92
48. Bos J.L. The ras gene family and human carcinogenesis. Mutat. Res. 195 (1988) 255-271
49. 2+] i in induction of c-fos, c-jun, and c-myc mRNA in rat PTE after oxidative stress. FASEB J. 6 (1992) 919-924
50. Überall F., Werner-Felmayer G., Schubert C., Grunicke H.H., Wachter H., and Fuchs D. Neopterin derivatives together with cyclic guanosine monophosphate induce c-fos gene expression. FEBS Lett. 352 (1994) 11-14
51. Toledano M.B., and Leonard W.J. Modulation of transcription factor NF-kappa B binding activity by oxidation-reduction in vitro. Proc. Natl. Acad. Sci. USA 88 (1991) 4328-4332
52. Hoffmann G., Schobersberger W., Frede S., Pelzer L., Fandrey J., Wachter H., Fuchs D., and Grote J. Neopterin activates transcription factor nuclear factor-kappa B in vascular smooth muscle cells. FEBS Lett. 391 (1996) 181-184
53. Cirillo P., Pacileo M., DE Rosa S., Calabrò P., Gargiulo A., Angri V., Granato-Corigliano F., Fiorentino I., Prevete N., DE Palma R., Mauro C., Leonardi A., and Chiariello M. Neopterin induces pro-atherothrombotic phenotype in human coronary endothelial cells. J. Thromb. Haemostasis 4 (2006) 2248-2255
54. Schroecksnadel K., Winkler C., Fischer B., Schennach H., Weiss G., and Fuchs D. Antioxidants down-regulate Th1-type immune response in vitro. Drug Metabol. Lett. 1 (2007) 166-171
55. Winkler C C., Wirleitner B., Schroecksnadel K., Schennach H., and Fuchs D. In vitro effects of beet root juice on stimulated and unstimulated peripheral blood mononuclear cells. Am. J. Biochem. Biotechnol. 1 (2005) 181-186
56. Winkler C C., Wirleitner B., Schroecksnadel K., Schennach H., and Mur E. D. St. John's wort (Hypericum perforatum) counteracts cytokine-induced tryptophan catabolism in vitro. Biol. Chem. 385 (2004) 1197-1202
57. Melichar B., Solichova D., and Freedman R.S. Neopterin as an indicator of immune activation and prognosis in patients with gynecological malignancies. Int. J. Gynecol. Cancer 16 (2006) 240-252
58. Reibnegger G.J., Bichler A.H., Dapunt O., Fuchs D.N., Fuith L.C., Hausen A., Hetzel H., Lutz H., Werner E.R., and Wachter H. Neopterin as a prognostic indicator in patients with carcinoma of the uterine cervix. Cancer Res. 46 (1986) 950-955
59. Reibnegger G., Hetzel H., Fuchs D., Fuith L.C., Hausen A., Werner E.R., and Wachter H. Clinical significance of neopterin for prognosis and follow-up in ovarian cancer. Cancer Res. 47 (1987) 4977-4981
60. Bayram M., Bayram O., Boyunaga H., and Ozer G. A research on the level of urine neopterin to see if it may provide a vital clue for a provisional diagnosis of breast cancer in menopausal women. Maturitas 48 (2004) 432-437
61. Hausen A., Fuchs D., Grunewald K., Huber H., Koenig K., and Wachter H. Urinary neopterine as marker for haematological neoplasias. Clin. Chim. Acta 117 (1981) 297-305
62. Piccinini L., Zironi S., Federico M., Pini L.A., and Luppi G. Urinary neopterin in malignant lymphoma. Int. J. Biol. Markers 6 (1991) 231-236
63. Reibnegger G., Krainer M., Herold M., Ludwig H., Wachter H., and Huber H. Predictive value of interleukin-6 and neopterin in patients with multiple myeloma. Cancer Res. 51 (1991) 6250-6253
64. Lewenhaupt A., Ekman P., Eneroth P., Eriksson A., Nilsson B., and Nordström L. Serum levels of neopterin as related to the prognosis of human prostatic carcinoma. Eur. Urol. 12 (1986) 422-425
65. Kawasaki H., Watanabe H., Yamada S., Watanabe K., and Suyama A. Prognostic significance of urinary neopterin levels in patients with hepatocellular carcinoma. Tohoku J. Exp. Med. 155 (1988) 311-318
66. Melichar B., Solichova D., Melicharova K., Malirova E., Cermanova M., and Zadak Z. Urinary neopterin in patients with advanced colorectal carcinoma. Int. J. Biol. Markers 21 (2006) 190-198
67. Fuchs D D., Weiss G., Reibnegger G., and Wachter H. The role of neopterin as a monitor of cellular activation in transplantation, inflammatory, infectious and malignant disease. Crit. Rev. Clin. Chem. 29 (1992) 307-341
68. Werner-Felmayer G., Werner E.R., Fuchs D., Hausen A., Reibnegger G., and Wachter H. Neopterin formation and tryptophan degradation by a human myelomonocytic cell line (THP-1) upon cytokine treatment. Cancer Res. 50 (1990) 2863-2867
69. Speth C., Stoeckl G., Fuchs D., Wirleitner B., Widner B., Würzner R., Mohsenipour I., and Dierich M.P. Inflammation marker 7,8-dihydroneopterin induces apoptosis of neurons and glial cells - potential contribution to neurodegenerative processes. Immunobiology 202 (2000) 460-476
70. Thiounn N., Pages F., Flam T., Tartour E., Mosseri V., Zerbib M., Beuzeboc P., Deneux L., Fridman W.H., and Debre B. IL-6 is a survival prognostic factor in renal cell carcinoma. Immunol. Lett. 58 (1997) 121-124
71. Weinlich G., Murr C., Richardsen L., Winkler C., and Fuchs D. Decreased serum tryptophan concentration predicts poor prognosis in malignant melanoma patients. Dermatology 214 (2007) 8-14
72. Taylor M.W., and Feng G.S. Relationship between interferon-gamma, indoleamine 2,3-dioxygenase, and tryptophan catabolism. FASEB J. 5 (1991) 2516-2522
73. Fuchs D., Moeller A.A., Reibnegger G., Stoeckle E., Werner E.R., and Wachter H. Decreased serum tryptophan in patients with HIV-1 infection correlates with increased serum neopterin and with neurologic/psychiatric symptoms. J. Acquir. Immune Defic. Syndr. 3 (1990) 873-876
74. Schroecksnadel K., Wirleitner B., Winkler C., and Fuchs D. Monitoring tryptophan metabolism in chronic immune activation. Clin. Chim. Acta 364 (2006) 82-90
75. Huang A., Fuchs D., Widner B., Glover C., Henderson D.C., and Allen-Mersh T.G. Serum tryptophan decrease correlates with immune activation and impaired quality of life in colorectal cancer. Br. J. Cancer 86 (2002) 1691-1696
76. Pfefferkorn E.R. Interferon gamma blocks the growth of Toxoplasma gondii in human fibroblasts by inducing the host cells to degrade tryptophan. Proc. Natl. Acad. Sci. USA 81 (1984) 908-912
77. Hwu P., Du M.X., Lapointe R., Do M., Taylor M.W., and Young H.A. Indoleamine 2,3-dioxygenase production by human dendritic cells results in the inhibition of T-cell proliferation. J. Immunol. 164 (2000) 3596-3599
78. Munn D.H., Shafizadeh E., Attwood J.T., Bondarev I., Pashine A., and Mellor A.L. Inhibition of T-cell proliferation by macrophage tryptophan catabolism. J. Exp. Med. 189 (1999) 1363-1372
79. Munn D.H., Sharma M.D., Lee J.R., Jhaver K.G., Johnson T.S., Keskin D.B., Marshall B., Chandler P., Antonia S.J., Burgess R., Slingluff Jr. C.L., and Mellor A.L. Potential regulatory function of human dendritic cells expressing indoleamine 23-dioxygenase. Science 297 (2002) 1867-1870
80. Grohmann U., Fallarino F., and Puccetti P. Tolerance, DCs and tryptophan: much ado about IDO. Trends Immunol. 24 (2003) 242-248
81. Uyttenhove C., Pilotte L., Théate I., Stroobant V., Colau D., Parmentier N., Boon T., and Van den Eynde B.J. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat. Med. 9 (2003) 1269-1274
82. Werner E.R., Werner-Felmayer G., Fuchs D., Hausen A., Reibnegger G., and Wachter H. Parallel induction of tetrahydrobiopterin biosynthesis and indoleamine 2,3-dioxygenase activity in human cells and cell lines by interferon-gamma. Biochem. J. 262 (1989) 861-866
83. Schroecksnadel K., Winkler C., Fuith L.C., and Fuchs D. Tryptophan degradation in patients with gynecological cancer correlates with immune activation. Cancer Lett. 223 (2005) 323-329
84. Fuchs D., Malkovsky M., Reibnegger G., Werner E.R., Forni G., and Wachter H. Endogenous release of interferon-gamma and diminished response of peripheral blood mononuclear cells to antigenic stimulation. Immunol. Lett. 23 (1989) 103-108
85. Wood K.J., and Sawitzki B. Interferon gamma: a crucial role in the function of induced regulatory T cells in vivo. Trends Immunol. 27 (2006) 183-187
86. Amadori A., Wirleitner B., Diez-Ruiz A., Veronesi A., Chieco-Bianchi L., and Fuchs D. Neopterin production in SCID mice injected with human peripheral blood mononuclear cells. Immunobiology 203 (2001) 642-649
87. Loeb S., Koenigsrainer A., Zieker D., Brücher B.L., Rammensee H.G., Opelz G., and Terness P. IDO1 and IDO2 are expressed in human tumors: levo- but not dextro-1-methyl tryptophan inhibits tryptophan catabolism. Cancer Immunol. Immunother. 58 (2009) 153-157
88. Bruera E. ABC of palliative care Anorexia, cachexia, and nutrition. Brit. Med. J. 315 (1997) 1219-1222
89. Tisdale M.J. Wasting in cancer. J. Nutr. 129 (1999) 243S-246S
90. Moldawer L.L., and Copeland III E.M. Proinflammatory cytokines, nutritional support, and the cachexia syndrome: interactions and therapeutic options. Cancer 79 (1997) 1828-1839
91. Ramos E.J., Suzuki S., Marks D., Inui A., Asakawa A., and Meguid M.M. Cancer anorexia-cachexia syndrome: cytokines and neuropeptides. Curr. Opin. Clin. Nutr. Metab. Care 7 (2004) 427-434
92. Denz H., Orth B., Weiss G., Herrmann R., Huber P., Wachter H., and Fuchs D. Weight loss in patients with hematological neoplasias is associated with immune system stimulation. Clin. Investig. 71 (1993) 37-41
93. Iwagaki H., Hizuta A., Tanaka N., and Orita K. Decreased serum tryptophan in patients with cancer cachexia correlates with increased serum neopterin. Immunol. Invest. 24 (1995) 467-478
94. Zhang F., Basinski M.B., Beals J.M., Briggs S.L., Churgay L.M., Clawson D.K., DiMarchi R.D., Furman T.C., Hale J.E., Hsiung H.M., Schoner B.E., Smith D.P., Zhang X.Y., Wery J.P., and Schevitz R.W. Crystal structure of the obese protein leptin-E100. Nature 387 (1997) 206-209
95. Billington C.J., Briggs J.E., Harker S., Grace M., and Levine A.S. Neuropeptide Y in hypothalamic paraventricular nucleus: a center coordinating energy metabolism. Am. J. Physiol. 266 (1994) R1765-R1770
96. Sherry B.A., Gelin J., Fong Y., Marano M., Wei H., Cerami A., Lowry S.F., Lundholm K.G., and Moldawer L.L. Anticachectin/tumor necrosis factor-alpha antibodies attenuate development of cachexia in tumor models. FASEB J. 3 (1989) 1956-1962
97. Inui A. Cancer anorexia-cachexia syndrome: are neuropeptides the key. Cancer Res. 59 (1999) 4493-4501
98. Kurzrock R. The role of cytokines in cancer-related fatigue. Cancer 92 (2001) 1684-1688
99. Zangerle R., Reibnegger G., Wachter H., and Fuchs D. Weight loss in HIV-1 infection is associated with immune activation. AIDS 7 (1993) 175-181
100. Bron D., Meuleman N., and Mascaux C. Biological basis of anemia. Semin. Oncol. 28 (2001) 1-6
101. Fuith L.C., Fuchs D., Reibnegger G., and Wachter H. Cellular immune activation and erythropoiesis in gynaecological cancer. Lancet 1 (1989) 908
102. Weiss G., Schroecksnadel K., Mattle V., Winkler C., Konwalinka G., and Fuchs D. Possible role of cytokine-induced tryptophan degradation in anaemia of inflammation. Eur. J. Haematol. 72 (2004) 130-134
103. Weiss G., and Goodnough L.T. Anemia of chronic disease. New Engl. J. Med. 352 (2005) 1011-1023
104. Denz H., Huber P., Landmann R., Orth B., Wachter H., and Fuchs D. Association between the activation of macrophages changes of iron metabolism and the degree of anaemia in patients with malignant disorders. Eur. J. Haematol. 48 (1992) 244-248
105. Fuchs D., Zangerle R., Artner-Dworzak E., Weiss G., Fritsch P., Tilz G.P., Dierich M.P., and Wachter H. Association between immune activation, changes of iron metabolism and anaemia in patients with HIV infection. Eur. J. Haematol. 50 (1993) 90-94
106. Means Jr. R.T., and Krantz S.B. Progress in understanding the pathogenesis of the anemia of chronic disease. Blood 80 (1992) 1639-1647
107. Jelkmann W.E., Fandrey J., Frede S., and Pagel H. Inhibition of erythropoietin production by cytokines. Implications for the anemia involved in inflammatory states. Ann. NY Acad. Sci. 718 (1994) 300-309
108. Theurl I., Mattle V., Seifert M., Mariani M., Marth C., and Weiss G. Dysregulated monocyte iron homeostasis and erythropoietin formation in patients with anemia of chronic disease. Blood 107 (2006) 4142-4148
109. Jelkmann W. Proinflammatory cytokines lowering erythropoietin production. J. Interferon Cytokine Res. 18 (1998) 555-559
110. Schobersberger W., Jelkmann W., Fandrey J., Frede S., Wachter H., and Fuchs D. Neopterin-induced suppression of erythropoietin production in vitro. Pteridines 6 (1995) 12-16
111. Kanbe E., Hatta Y., Tsuboi I., Harada T., Koshinaga M., Inoue T., and Aizawa S. Effects of neopterin on the hematopoietic microenvironment of senescence-accelerated mice (SAM). Biol. Pharm. Bull. 29 (2006) 43-48
112. Minami A., Tsuboi I., Harada T., Fukumoto T., Hiramoto M., Koshinaga M., Hirabayashi Y., Kanno J., Inoue T., and Aizawa S. Inflammatory biomarker, neopterin, suppresses B lymphopoiesis for possible facilitation of granulocyte responses, which is severely altered in age-related stromal-cell-impaired mice, SCI/SAM,. Exp. Biol. Med. 23 (2007) 134-145 (Maywood)
113. Selleri C., Maciejewski J.P., Sato T., and Young N.S. Interferon-gamma constitutively expressed in the stromal microenvironment of human marrow cultures mediates potent hematopoietic inhibition. Blood 87 (1996) 4149-4157
114. Ludwiczek S., Aigner E., Theurl I., and Weiss G. Cytokine-mediated regulation of iron transport in human monocytic cells. Blood 101 (2003) 4148-4154
115. Weiss G., Goossen B., Doppler W., Fuchs D., Pantopoulos K., Werner-Felmayer G., Grünewald K., Wachter H., and Hentze M.W. Translational regulation via iron-responsive elements by the nitric oxide/NO-synthase pathway. EMBO J. 12 (1993) 3651-3657
116. Pantopoulos K., and Hentze M.W. Rapid responses to oxidative stress mediated by iron regulatory protein. EMBO J. 14 (1995) 2917-2924;
117. Drapier J.C., Hirling H., Wietzerbin J., Kaldy P., and Kuhn L.C. Biosynthesis of nitric oxide activates iron regulatory factor in macrophages. EMBO J. 12 (1993) 3643-3649
118. Rosen G.M., Pou S., Ramos C.L., Cohen M.S., and Britigan B.E. Free radicals and phagocytic cells. FASEB J. 9 (1995) 200-209
119. Bower J.E., Ganz P.A., Aziz N., and Fahey J.L. Fatigue and proinflammatory cytokine activity in breast cancer survivors. Psychosom. Med. 64 (2002) 604-611
120. Neurauter G., Schroecksnadel K., Scholl-Bürgi S., Sperner-Unterweger B., Schubert C., Ledochowski M., and Fuchs D. Chronic immune stimulation correlates with reduced phenylalanine turnover. Curr. Drug Metab. 9 (2008) 622-627
121. Widner B., Laich A., Sperner-Unterweger B., Ledochowski M., and Fuchs D. Neopterin production, tryptophan degradation, and mental depression - what is the link?. Brain Behav. Immun. 16 (2002) 590-595
122. Owens M.J., and Nemeroff C.B. Role of serotonin in the pathophysiology of depression: focus on the serotonin transporter. Clin. Chem. 40 (1994) 288-295
123. Heyes M.P., Saito K., Crowley J.S., Davis L.E., Demitrack M.A., Der M., Dilling L.A., Elia J., Kruesi M.J., Lackner A., et al. Quinolinic acid and kynurenine pathway metabolism in inflammatory and non-inflammatory neurological disease. Brain 115 Pt 5 (1992) 1249-1273
124. Weiss G G., Diez-Ruiz A A., Murr C C., Theurl I I., and Fuchs D. Tryptophan metabolites as scavengers of reactive oxygen and chlorine species. Pteridines 13 (2002) 140-144
125. Maes M., Scharpe S., Meltzer H.Y., Okayli G., Bosmans E., D'Hondt P., Vanden Bossche B.V., and Cosyns P. Increased neopterin and interferon-gamma secretion and lower availability of L-tryptophan in major depression: further evidence for an immune response. Psychiatry Res. 54 (1994) 143-160
126. Murr C., Widner B., Sperner-Unterweger B., Ledochowski M., Schubert C., and Fuchs D. Immune reaction links disease progression in cancer patients with depression. Med. Hypotheses 55 (2000) 137-140
127. DeVane C.L. Differential pharmacology of newer antidepressants. J. Clin. Psychiatry 59 Suppl. 20 (1998) 85-93
128. Bellmann-Weiler R., Schroecksnadel K., Holzer C., Larcher C., Fuchs D., and Weiss G. IFN-gamma mediated pathways in patients with fatigue and chronic active Epstein Barr virus-infection. J. Affect. Disord. 108 (2008) 171-176
129. Schroecksnadel K., Fiegl M., Prassl K., Winkler C., Denz H.A., and Fuchs D. Diminished quality of life in patients with cancer correlates with tryptophan degradation. J. Cancer Res. Clin. Oncol. 133 (2007) 477-485
130. Neurauter G., Grahmann A.V., Klieber M., Zeimet A., Ledochowski M., Sperner-Unterweger B., and Fuchs D. Serum phenylalanine concentrations in patients with ovarian carcinoma correlate with concentrations of immune activation markers and of isoprostane-8. Cancer Lett. 272 (2008) 141-147
131. Gallucci S., and Matzinger P. Danger signals: SOS to the immune system. Curr. Opin. Immunol. 13 (2001) 114-119
132. Murr C., Schroecksnadel K., Winklhofer-Roob B.M., Mangge H., Boehm B.O., Winkelmann B.R., Maerz W., and Fuchs D. Inverse association between serum concentrations of neopterin and antioxidants in patients with and without angiographic coronary artery disease. Atherosclerosis 202 (2009) 543-549